Journal of Medical Economics, Volume 21, Issue 6 (2018)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Journal of Medical Economics, Volume 21, Issue 6 (2018)

See all volumes and issues
Vol 27, 2024 Vol 26, 2023 Vol 25, 2022 Vol 24, 2021 Vol 23, 2020 Vol 22, 2019 Volume 21, 2018 Vol 20, 2017 Vol 19, 2016 Vol 18, 2015 Vol 17, 2014 Vol 16, 2013 Vol 15, 2012 Vol 14, 2011 Vol 13, 2010 Vol 12, 2009 Vol 11, 2008 Vol 10, 2007 Vol 9, 2006 Vol 8, 2005 Vol 7, 2004 Vol 6, 2003 Vol 5, 2002 Vol 4, 2001 Vol 3, 2000 Vol 2, 1999 Vol 1, 1998
Download citations Download PDFs Download issue

Oncology

Article
Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers
Anita Chawla, Miranda Peeples, Nanxin Li, Rachel Anhorn, Jason Ryan & James Signorovitch
Pages: 543-552
Published online: 19 Jan 2018
AbstractforReal-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers | Full Text | References | PDF (1.2 MB) | Supplemental
  • 2049 Views
  • 10 CrossRef citations
  • 0Altmetric
Free Access

Immunology

Article Commentary
The economic advantage of allergen immunotherapy over drug treatment in respiratory allergy
Cristoforo Incorvaia, Bruna L. Gritti & Erminia Ridolo
Pages: 553-555
Published online: 10 Jan 2018
First Page PreviewforThe economic advantage of allergen immunotherapy over drug treatment in respiratory allergy | Full Text | References | PDF (301.5 KB)
  • 485 Views
  • 5 CrossRef citations
  • 0Altmetric
Free Access

Oncology

Article
Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations
Eytan M. Stein, Gaetano Bonifacio, Dominick Latremouille-Viau, Annie Guerin, Sherry Shi, Patrick Gagnon-Sanschagrin, Owanate Briggs & George J. Joseph
Pages: 556-563
Published online: 22 Jan 2018
AbstractforTreatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations | Full Text | References | PDF (851.8 KB) | Supplemental
  • 2042 Views
  • 27 CrossRef citations
  • 0Altmetric
Free Access

Dermatology

Article
Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population
Seina Lee, Lin Xie, Yuexi Wang, Neel Vaidya & Onur Baser
Pages: 564-570
Published online: 15 Feb 2018
AbstractforComorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population | Full Text | References | PDF (1.1 MB)
  • 1177 Views
  • 8 CrossRef citations
  • 0Altmetric
Free Access

Addiction Medicine

Article
Estimating the public economic consequences of introducing varenicline smoking cessation therapy in South Korea using a fiscal analytic framework
Mark P. Connolly, Christine L. Baker & Nikolaos Kotsopoulos
Pages: 571-576
Published online: 13 Feb 2018
AbstractforEstimating the public economic consequences of introducing varenicline smoking cessation therapy in South Korea using a fiscal analytic framework | Full Text | References | PDF (625.2 KB)
  • 504 Views
  • 1 CrossRef citations
  • 0Altmetric
Free Access

Oncology

Article
Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States
Zheng-Yi Zhou, Alex Mutebi, Simeng Han, Arielle G. Bensimon, Marie Louise Ricculli, Jipan Xie, Anand Dalal & Ken Culver
Pages: 577-586
Published online: 12 Mar 2018
AbstractforCost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States | Full Text | References | PDF (1.8 MB) | Supplemental
  • 1642 Views
  • 11 CrossRef citations
  • 0Altmetric
Free Access

Cardiovascular

Article
Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results
Philip S. Wells, Anthonie W. A. Lensing, Lloyd Haskell, Bennett Levitan, François Laliberté, Michael Durkin, Veronica Ashton, Yongling Xiao, Concetta Crivera, Dominique Lejeune, Jeff Schein & Patrick Lefebvre
Pages: 587-594
Published online: 16 Mar 2018
AbstractforCost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results | Full Text | References | PDF (1 MB)
  • 837 Views
  • 1 CrossRef citations
  • 0Altmetric
Free Access
Article
Resource utilization and charges of patients with and without diagnosed venous thromboembolism during primary hospitalization and after elective inpatient surgery: a retrospective study
Aryana Sepassi, Francine Chingcuanco, Ronald Gordon, Angela Meier, Victoria Divino, Mitch DeKoven & Rami Ben-Joseph
Pages: 595-602
Published online: 01 Mar 2018
AbstractforResource utilization and charges of patients with and without diagnosed venous thromboembolism during primary hospitalization and after elective inpatient surgery: a retrospective study | Full Text | References | PDF (941 KB)
  • 531 Views
  • 3 CrossRef citations
  • 0Altmetric
Free Access

Oncology

Letter
Response to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083–93
Mark Bensink, Christine Edwards, Charles Bowers & Jon Campbell
Pages: 603-605
Published online: 12 Apr 2018
First Page PreviewforResponse to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083–93 | Full Text | References | PDF (366 KB)
  • 443 Views
  • 1 CrossRef citations
  • 0Altmetric
Free Access
Letter
Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia
Ali McBride, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham & Sanjeev Balu
Pages: 606-609
Published online: 12 Apr 2018
First Page PreviewforReply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia | Full Text | References | PDF (413.4 KB)
  • 525 Views
  • 8 CrossRef citations
  • 0Altmetric
Free Access

Otolaryngology

Article
Disease-related expenditures and revision rates in chronic rhinosinusitis patients after endoscopic sinus surgery
Tina D. Hunter, Adam S. DeConde & R. Peter Manes
Pages: 610-615
Published online: 03 Apr 2018
AbstractforDisease-related expenditures and revision rates in chronic rhinosinusitis patients after endoscopic sinus surgery | Full Text | References | PDF (545.6 KB)
  • 1058 Views
  • 13 CrossRef citations
  • 0Altmetric
Free Access

Cardiovascular

Article
Prospective utility study of patients with multiple cardiovascular events
Rhys D. Pockett, Phil McEwan, Joshua Ray, Irwin Tran, Simon Shutler, Steven Martin, Zaheer Yousef & Ameet Bakhai
Pages: 616-621
Published online: 03 Apr 2018
AbstractforProspective utility study of patients with multiple cardiovascular events | Full Text | References | PDF (557.4 KB)
  • 1183 Views
  • 6 CrossRef citations
  • 0Altmetric
Free Access

Neurology

Article
Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database
Debajyoti Bhowmik, Dionne M. Hines, Michele Intorcia & Rolin L. Wade
Pages: 622-628
Published online: 12 Apr 2018
AbstractforEconomic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database | Full Text | References | PDF (757 KB)
  • 1127 Views
  • 10 CrossRef citations
  • 0Altmetric
Free Access

Respiratory Medicine

Article
Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care
Christopher F. Bell, Anna D. Coutinho, Eileen Farrelly, Tasneem Lokhandwala & Pamela Landsman-Blumberg
Pages: 629-638
Published online: 24 Apr 2018
AbstractforClinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care | Full Text | References | PDF (1,012.9 KB) | Supplemental
  • 518 Views
  • 1 CrossRef citations
  • 0Altmetric
Free Access

Explore articles